TOKYO -- Japan's Takeda Pharmaceutical has decided to sell its nonprescription drugs business, including vitamin drug Alinamin, to major U.S. private equity firm Blackstone Group for about 250 billion yen ($2.37 billion)
Pharmaceuticals
Takeda to sell OTC drug unit to Blackstone for $2.3bn
Japanese pharmaceutical maker in bid to reduce debt inflated by Shire purchase
Takeda Pharmaceutical will sell wholly owned subsidiary Takeda Consumer Healthcare Company, which is involved in Alinamin and other medicine line.
Read Next
Latest on Pharmaceuticals
